Izrael - héber - Ministry of Health

novartis israel ltd - gemcitabine as hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 40 mg / 1 ml - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Izrael - héber - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Izrael - héber - Ministry of Health

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Izrael - héber - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

Izrael - héber - Ministry of Health

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

Izrael - héber - Ministry of Health

pfizer pharmaceuticals israel ltd - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w - 135 polysaccharide; neisseria meningitidis group y polysaccharide - אבקה וממס להכנת תמיסה להזרקה - neisseria meningitidis group y polysaccharide 5 mcg; neisseria meningitidis group w - 135 polysaccharide 5 mcg; neisseria meningitidis group c polysaccharide 5 mcg; neisseria meningitidis group a polysaccharide 5 mcg - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - nimenrix is indicated for active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135 and y.

Izrael - héber - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - תרחיף להזרקה - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of disease caused by streptococcus pneumoniae serotypes 1,3,4,5,6a, 6b, 7f, 9v, 14,18c,19a,19f, 23f (including sepsis, meningitis, bacteraemia, pneumonia and acute otitis media) in infants and children from 2 months to 5 years of age.in adults 50 years of age and older, prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f. this indication is based on immune responses elicited by prevnar 13. there have been no controlled trials in adults demonstrating a decrease in invasive pneumococcal disease or pneumococcal pneumonia after vaccination with prevnar 13.

Izrael - héber - Ministry of Health

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus - אבקה וממס להכנת תמיסה להזרקה - live attenuated mumps virus 10^3.7 ccid50; live attenuated rubella virus 10^3.0 ccid50; live attenuated measles virus 10^3.0 ccid50 - rubella, combinations with mumps, live attenuated - rubella, combinations with mumps, live attenuated - priorix is indicated for active immunisation of children from the age of 9 months or older, adolescents and adults against measles, mumps and rubella.

Izrael - héber - Ministry of Health

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Izrael - héber - Ministry of Health

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 400 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.